Comparing prophylaxis with episodic treatment in haemophilia A: Implications for clinical practice

Haemophilia

Volumn 13, Issue SUPPL. 2, 2007, Pages 4-9

  Manco Johnson, Marilyn ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b Mountain States Regional Hemophilia and Thrombosis Center   (United States)

Author keywords

Episodic; Factor VIII; Haemophilia; On demand; Prophylaxis; Randomized controlled study

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ARTHRALGIA; ARTHROPATHY; ARTICLE; CLINICAL EVALUATION; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; HEMARTHROSIS; HEMOPHILIA A; HUMAN; IMMOBILIZATION; JOINT FUNCTION; JOINT INJURY; JOINT RADIOGRAPHY; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COAGULANTS; FACTOR VIII; HEMARTHROSIS; HEMOPHILIA A; HUMANS; INFANT;

EID: 34447124678     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01533.x     Document Type: Article

References (34)

1. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003; 361: 1801-9.
2. Soucie JM, Evatt B, Jackson D. Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol 1998; 59: 288-94.
3. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9.
4. Manco-Johnson MJ, Riske B, Kasper CK. Advances in care of children with hemophilia. Semin Thromb Hemost 2003; 29: 585-94.
5. Rodriguez-Merchan EC. Management of musculoskeletal complications of hemophilia. Semin Thromb Hemost 2003; 29: 87-96.
6. Berntorp E, Astermark J, Bjorkman S et al. Consensus perspectives on prophylactic therapy for haemophilia: Summary statement. Haemophilia 2003; 9 (Suppl. 1): 1-4.
7. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
8. Nilsson IM, Hedner U, Ahlberg A. Haemophilia prophylaxis in Sweden. Acta Paediatr Scand 1976; 65: 129-35.
9. Manco-Johnson MJ. Update on treatment regimens: Prophylaxis vs. on-demand therapy. Semin Hematol 2003; 40: 3-9.
10. Panicker J, Warrier I, Thomas R, Lusher JM. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia 2003; 9: 272-8.
11. Petrini P, Lindvall N, Egberg N, Blomback M. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Pediatr Hematol Oncol 1991; 13: 280-7.
12. Manco-Johnson MJ, Nuss R, Geraghty S, Funk S, Kilcoyne R. Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol 1994; 47: 113-17.
13. Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients - a long-term follow-up. J Intern Med 1997; 241: 395-400.
14. World Health Organization. Report of Joint WHO/WFH Meeting on the Control of Haemophilia: Delivery of Treatment for Haemophilia. 2002. Available at: http://whqlibdoc.who.int/hq/2002/WHO_WFH_ISTH_WG_02.6.pdf.
15. National Hemophilia Foundation. MASAC Recommendations Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding). 2006. Available at: http://www.hemophilia.org/NHFWeb/ Resource/StaticPages/menu0/menu5/menu57/170.pdf.
16. Blanchette VS, McCready M, Achonu C, Abdolell M, Rivard G, Manco-Johnson MJ. A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres. Haemophilia 2003; 9 (Suppl. 1): 19-26.
17. Geraghty S, Dunkley T, Harrington C, Lindvall K, Maahs J, Sek J. Practice patterns in haemophilia A therapy - global progress towards optimal care. Haemophilia 2006; 12: 75-81.
18. Manco-Johnson MJ, Nuss R, Lear J et al. 32 P radiosynoviorthesis in children with hemophilia. J Pediatr Hematol Oncol 2002; 24: 534-39.
19. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001; 7: 392-6.
20. Ewenstein BM, Valentino LA, Journeycake JM et al. Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia 2004; 10: 1-20.
21. Hoots WK, Nugent DJ. Evidence for the benefits of prophylaxis in the management of hemophilia A. Thromb Haemost 2006; 96: 433-40.
22. Stobart K, Iorio A, Wu JK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2006; CD003429.
23. Aronstam A, Arblaster PG, Rainsford SG et al. Prophylaxis in haemophilia: A double-blind controlled trial. Br J Haematol 1976; 33: 81-90.
24. Aronstam A, Kirk PJ, McHardy J et al. Twice weekly prophylactic therapy in haemophilia A. J Clin Pathol 1977; 30: 65-7.
25. Carlsson M, Berntorp E, Bjorkman S, Lethagen S, Ljung R. Improved cost-effectiveness by pharmacokinetic dosing of factor VII in prophylactic treatment of haemophilia A. Haemophilia 1997; 3: 96-101.
26. Morfini M, Mannucci PM, Mariani G et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scand J Haematol 1976; 16: 41-7.
27. Gringeri A. Prospective controlled studies on prophylaxis: An Italian approach. Haemophilia 2003; 9 (Suppl. 1): 38-42.
28. Manco-Johnson MJ, Abshire TC, Brown D et al. Initial results of a randomized, prospective trial of prophylaxis to prevent joint disease in young children with Factor VIII (FVIII) deficiency. ASH Annual Meeting Abstracts 2005; 106: Abstract 3.
29. Feldman BM, Pai M, Rivard GE et al. Tailored prophylaxis in severe hemophilia A: Interim results from the first 5years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4: 1228-36.
30. Manco-Johnson MJ, Blanchette VS. North American prophylaxis studies for persons with severe haemophilia: Background, rationale and design. Haemophilia 2003; 9 (Suppl. 1): 44-8.
31. Pergantou H, Matsinos G, Papadopoulos A, Platokouki H, Aronis S. Comparative study of validity of clinical, X-ray and magnetic resonance imaging scores in evaluation and management of haemophilic arthropathy in children. Haemophilia 2006; 12: 241-7.
32. Doria AS, Babyn PS, Lundin B et al. Reliability and construct validity of the compatible MRI scoring system for evaluation of haemophilic knees and ankles of haemophilic children. Haemophilia 2006; 12: 503-13.
33. Manco-Johnson MJ, Nuss R, Funk S, Murphy J. Joint evaluation instruments for children and adults with haemophilia. Haemophilia 2000; 6: 649-57.
34. Hacker MR, Funk SM, Manco-Johnson MJ. The Colorado Haemophilia Paediatric Joint Physical Examination Scale: Normal values and interrater reliability. Haemophilia 2007; 13: 71-8.